Primary progressive multiple sclerosis (MS), comprising 10% to 15% of all cases of MS, is characterized by an insidious progression from the onset of disease, making it clinically distinct from the commonest form, relapsing remitting MS. Making the diagnosis can be challenging, and misdiagnosis and delay in diagnosis are common. Although no effective treatments are currently known, insights into the pathogenesis of this phenotype aid in understanding the processes that drive progression in all forms of MS.
Note: Text referenced in the Quintessentials Preferred Responses, which appear later in this issue, is indicated in yellow shading throughout this article.
Relationship Disclosure: Dr Hawker owns stock in Eli Lilly and Company.
Unlabeled Use of Products/Investigational Use Disclosure: Dr Hawker has nothing to disclose.